Tempest Therapeutics (TPST) Non Operating Income (2021 - 2026)
Tempest Therapeutics' (TPST) quarterly Non Operating Income came in at $6000.0 in Q2 2026, down 93.75% year-over-year from $96000.0 in Q2 2025, and down 89.29% quarter-over-quarter from $56000.0 in Q4 2025.
Powered by 
Analysis
Tempest Therapeutics (TPST) Non Operating Income (2021 - 2026) Analysis & Trends
Tempest Therapeutics has disclosed Non Operating Income across 6 years of filings, most recently posting $6000.0 for Q2 2026.
- In Q2 2026, Non Operating Income fell 93.75% year-over-year to $6000.0; the TTM figure through Jun 2026 stood at $244000.0 (down 10.29% YoY), while the FY2025 annual figure was $313000.0, up 71.04% from the prior year.
- Non Operating Income came in at $6000.0 for Q2 2026 at Tempest Therapeutics, down from $56000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $105000.0 in Q4 2024 to a low of -$394000.0 in Q2 2022.
- Average Non Operating Income over 5 years is -$53000.0, with a median of $6000.0 recorded in 2026.
- Year-over-year, Non Operating Income jumped 1820.0% in 2025 and sank 93.75% in 2026.
- Over 5 years, Non Operating Income stood at -$169000.0 in 2022, then jumped by 115.38% to $26000.0 in 2023, then jumped by 303.85% to $105000.0 in 2024, then sank by 46.67% to $56000.0 in 2025, then tumbled by 89.29% to $6000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $6000.0 in Q2 2026, $56000.0 in Q4 2025, and $86000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 27.08 Mn |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | - |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - | 3.88 Mn |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | -2.57 Mn |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | -15.04 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 1.77 Mn |
| 10 | Tempest Therapeutics | 3.41 Mn | 2.61 Mn | - | 6,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | -194,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -55,000.00 |
| Dec 31, 2022 | -169,000.00 |
| Sep 30, 2022 | -176,000.00 |
| Jun 30, 2022 | -394,000.00 |
| Mar 31, 2022 | -330,000.00 |
| Dec 31, 2021 | -441,000.00 |
| Sep 30, 2021 | -374,000.00 |
| Jun 30, 2021 | -273,000.00 |